Goldman Sachs’s Alder Biopharmaceuticals ALDR Stock Holding History

Goldman Sachs’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-50,000	Closed	-$1.04M	–	7135
2016 Q4	$1.04M	Buy	+50,000	New	+$1.3M	﹤0.01%	4417
2016 Q2	–	Sell	-50,000	Closed	-$1.23M	–	7386
2016 Q1	$1.23M	Buy	+50,000	New	+$1.16M	﹤0.01%	3920

Goldman Sachs's ALDR Position: Q4 2019 in Review

Goldman Sachs sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 1,859,760 shares — an estimated $35.1M sold.

Goldman Sachs first reported a position in ALDR in Q4 2014 and held it in 20 quarters. The position peaked at $45.3M in Q2 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.

Goldman Sachs reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
Goldman Sachs sold 1,859,760 Alder Biopharmaceuticals shares in Q4 2019, an estimated $35.1M.
Goldman Sachs first reported a position in Alder Biopharmaceuticals in Q4 2014 and held it in 20 quarters.
Goldman Sachs's Alder Biopharmaceuticals position peaked at $45.3M in Q2 2019.
0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.

Based on Goldman Sachs's 13F filing for Q4 2019, filed 14 Feb 2020.